VK2735 injection
VK2735 · Viking Therapeutics
Weekly injectable dual GIP/GLP-1 agonist in global pivotal obesity trials.
Selected study results
VENTURE · injectionMean body-weight reductionBody weight decreased 14.7% · 13 weeks · Phase 2
Mean body-weight reduction · 13 weeks
Study focus: Weight management without type 2 diabetes
Adults with obesity or overweight and a weight-related complication, without diabetes · 15 mg once weekly vs placebo · Trial N=176 · Least-squares means; efficacy population; mixed model. Results & methods ↗
Short dose-finding trial. These are Phase 2 results, not the ongoing VANQUISH Phase 3 outcomes. At 15 mg, 20% discontinued treatment early versus 14% with placebo.
VK2735 maintenance · every other weekProportion of prior weight loss retained at Week 33Prior weight loss retained: 90% · 12 weeks of maintenance · Phase 1
Proportion of prior weight loss retained at Week 33 · 12 weeks of maintenance
Study focus: Weight-loss maintenance
Up to 97% of prior weight loss was retained in an individual every-other-week dose cohort.
Adults with obesity after a 21-week VK2735 induction period · 21-week weekly induction, then every-other-week maintenance vs placebo · N not included in this summary · Sponsor topline; combined maintenance regimens. Results & methods ↗
Short Phase 1 maintenance period. The chart shows combined regimen results; dose-cohort maxima are noted separately. These findings do not establish long-term maintenance efficacy.
VK2735 maintenance · monthlyProportion of prior weight loss retained at Week 33Prior weight loss retained: 85% · 12 weeks of maintenance · Phase 1
Proportion of prior weight loss retained at Week 33 · 12 weeks of maintenance
Study focus: Weight-loss maintenance
Up to 90% of prior weight loss was retained in an individual monthly dose cohort.
Adults with obesity after a 21-week VK2735 induction period · 21-week weekly induction, then monthly maintenance vs placebo · N not included in this summary · Sponsor topline; combined maintenance regimens. Results & methods ↗
Short Phase 1 maintenance period. The chart shows combined regimen results; dose-cohort maxima are noted separately. These findings do not establish long-term maintenance efficacy.
Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.
Mechanism at a glance
Obesity stage by formulation
Latest: VANQUISH-1 and VANQUISH-2 Phase 3 obesity trials are fully enrolled. Part 2 of the separate exploratory maintenance study began in October 2026; Viking corrected its dosing description on October 14.
Next: VANQUISH Phase 3 outcomes. Maintenance Part 2 tests daily oral, monthly subcutaneous, or every-other-week subcutaneous dosing after 21 weeks of weekly injections; results are expected in 2027. This exploratory study is separate from the Phase 3 registration program.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies2 records
VANQUISH-1
Weight managementAdults with obesity or overweight and a weight-related comorbidity, without type 2 diabetes.
VANQUISH-2
Weight management with type 2 diabetesAdults with obesity or overweight and type 2 diabetes.
Phase 2 studies1 record
VENTURE
Weight management13-week dose-ranging obesity study; historical efficacy context for the Phase 3 injectable program.
